Sign in
Taking people in United StatesPhase 2

Resistant Starch Tested in Women with Polycystic Ovary Syndrome

Tests a starch supplement against placebo in women with PCOS and metabolic syndrome.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
Combined Oral Contraceptive Pill and Resistance Starch
Status
Recruiting
Phase
Phase 2
People taking part
100 people, planned
Started
10 Jun 2025
Expected to end
Apr 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • wheat dextrin
  • Oral Contraceptives, Low-Dose
  • Maltodextrin
Record updated
1 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 to 40 with polycystic ovary syndrome (PCOS) and a higher body weight. It studies the contraceptive pill, then 12 weeks of resistant starch or placebo.

Age
18 to 40 years
Sex
Women only
Disease stage
PCOS diagnosed by the Rotterdam criteria (irregular or missing ovulation, high male hormones, and polycystic ovaries on ultrasound or high AMH). BMI from 25 to 48 kg/m².
Earlier treatment
No antibiotics for at least 3 months before randomization. No current use of probiotics or laxatives. No medicines that affect weight or metabolism, such as lipid lowering medications.
Biomarker or test result
Women with regular bleeding who may still not ovulate need a mid-luteal progesterone (P4) level below 3 ng/dL.

Main reasons for not taking part

  • Type 1 or type 2 diabetes
  • History of bariatric surgery
  • Crohn's disease or ulcerative colitis
  • Dietary fiber intake above 20 g/day
  • Medical conditions that make the contraceptive pill unsafe, such as blood clots, stroke or known heart disease

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Women between ages of 18-40 years with BMI greater than or equal to 25 kg/m² to less than or equal to 48 kg/m² diagnosed with PCOS defined by the Rotterdam criteria based on a history of chronic anovulation (8 or fewer periods), androgen excess [defined as total serum testosterone, free testosterone or a FAI greater than or equal to 90% of the upper limit of normal) or hirsutism (Ferriman-Gallwey score greater than 6 for Hispanics/ Black and greater than or equal to 2 for women of Asian descent)] and polycystic ovaries as defined by a pelvic ultrasound (20 or more follicles or ovarian vol greater than 10cm3) or elevated AMH
  • For women with more regular bleeding patterns, but who are suspected to be experiencing periodic anovulatory bleeding, a midluteal progesterone (P4) level less than 3ng/dL will be evidence of ovulatory dysfunction and qualify as anovulation
  • Women with only hyperandrogenic PCOS phenotype (hyperandrogenism + one more criteria) will be included to decrease the heterogeneity of the cohort and as metabolic risks are increased in these women compared to normo-androgenic women with PCOS
  • Subjects should be willing to avoid pregnancy for the entire duration of the study

Who cannot take part

  • Subjects taking medications that affect weight or metabolic parameters (e.g. lipid lowering medications)
  • Subjects could not have taken antibiotics for at least 3 months prior to randomization visit
  • Subjects with history of bariatric surgery
  • Those who are unable to comply with the study procedures, for instance due to mental illness, substance abuse, or participation in other studies
  • History of Crohn's disease and ulcerative colitis as well as current use of probiotics and laxatives are excluded
  • Subjects with medical conditions that are contraindications to use of OCP and other medical conditions such as:; Type 1 or 2 diabetes; liver disease or dysfunctional liver (AST/ALT greater than 2x normal or a total bilirubin greater than 2.5 mg/dL); renal disease (BUN greater than 30 mg/dL or serum creatinine greater than 1.4 mg/dL); severe anemia (hemoglobin less than 10 mg/dL); alcohol abuse; poorly controlled hypertension; TG greater than 250 mg/dl; chronic inflammatory conditions such as psoriasis; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; known heart disease (New York Heart Association Class II or higher); history of cervical carcinoma, endometrial carcinoma, or breast carcinoma, adrenal or ovarian tumor secreting androgens, and Cushing's syndrome -
  • Subjects with other causes for irregular menses such as pregnancy, lactation, untreated hypothyroidism, untreated hyperprolactinemia and premature menopause
  • Subjects with late onset adrenal hyperplasia
  • Subjects with greater than 20 g/day of dietary fiber intake based on pre-screening ASA-24 survey will be excluded

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • University of PennsylvaniaPhiladelphia, United StatesContact: Anuja Dokras, MD PhDTaking people

About the trial

What the trial wants to find out

This study will enroll women with PCOS to study the effects of first line therapy, oral contraceptive pills, and then either 12 weeks of resistant starch or 12 weeks of placebo to explore if resistant starch improves cardiometabolic parameters or impacts gut dysbiosis compared to placebo.

The 2 groups in the trial

  • Resistant StarchExisting treatment, for comparison

    wheat dextrin

    Treatment: wheat dextrin and Oral Contraceptives, Low-Dose

  • PlaceboPlacebo, for comparison

    maltodextrin

    Treatment: Oral Contraceptives, Low-Dose and Maltodextrin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Resistant Starch Usage in Polycystic Ovary Syndrome: Impact on Cardiometabolic Dysfunction and the Gut Microbiome (CORS-PCOS)
Plain-language title
Resistant Starch Tested in Women with Polycystic Ovary SyndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06852365, who can take part
Record updated
1 June 2026